MindMed

Psychedelic research is moving at an outstanding pace - and sometimes it's hard to keep up! Our CMO, Dan Karlin answers questions such as, "What is FDA breakthrough designation?" and more. Watch the video here: https://lnkd.in/ekYVEVfW

We are thrilled to announce that MindMed has been included in the Russell 2000® Index and the broad-market Russell 3000® Index. “MindMed’s inclusion in the Russell 2000® index marks an important milestone that reflects our commitment to addressing the unmet medical needs for people with brain health disorders." - Robert Barrow, CEO of Mindmed Based on market-capitalization rankings and style attributes, the #Russell3000 Index features the 3,000 largest U.S.-traded stocks. This inclusion means automatic membership in either the large-cap Russell 1000® Index or the small-cap Russell 2000® Index, along with the appropriate growth and value style indexes. Read the full press release here: https://lnkd.in/dH6hWF5J

We were honored to have Robert Barrow, our CEO, present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference earlier this morning. In case you missed it, check out the replay of the fireside chat here: https://lnkd.in/d3ERM4zQ

We’re rethinking brain health, working to unlock the therapeutic potential of psychedelics to meet unmet patient needs. Our investigational treatment (in development) has shown the potential to increase baseline connectivity between brain regions by activating serotonin-2A receptors. What are the potential impacts of increased neuronal connectivity? → Altered perception, behavior, and mood → Intensified thoughts, emotions, and sensory experiences → Creation of new neural pathways (neurogenesis) → Reduced rumination and anxiety Learn more today.

Check out today’s news release regarding our development program for MM120 in the treatment of generalized anxiety disorder in adults. https://lnkd.in/dstCu2CJ

1940 - 1950 #LSD, discovered by Swiss chemist Albert Hofmann, revolutionized psychiatric research. Its potential to model psychosis and aid psychotherapy opened new frontiers, showing remarkable promise in treating conditions like alcoholism and depression. These early findings set the foundation for exploring #psychedelic potential for treating a variety of other mental disorders.

In the field of mental health, research is revealing the remarkable potential of psychedelics to act as catalysts for significant positive change in mental health.

Anxiety can influence work performance, making it difficult to concentrate, meet deadlines, or engage with colleagues. It can affect personal relationships, causing strain and misunderstanding among friends, family, and partners. Social activities can become daunting, leading to isolation and a sense of being disconnected. Even routine tasks, like running errands or making decisions, can feel insurmountable. On this Anxiety Awareness Day, let's take a moment to educate ourselves and others about anxiety. Learn to recognize how it can impact different areas of life, offer support to friends and loved ones, and advocate for better mental health resources. Together, we can create a community of understanding and compassion, where those living with anxiety feel seen, heard, and supported. #anxiety #AnxietyAwarenessDay #GAD

Our Chief Medical Officer, Dr. Dan Karlin, recently joined an esteemed panel that highlighted the novel approaches to developing new classes of neuropsychiatry medications, including psychedelics at the Biotechnology Innovation Organization International Convention. Entitled "Challenging Biotech's One-Track Mind When it Comes to Neuropsychiatric Drug Innovation," Dr. Karlin was joined by Laxminarayan Bhat, PhD, Amit Etkin, MD, David Benshoof Klein, along with moderator Heather McKenzie. MindMed is committed to understanding mental health disorders, starting with Generalized Anxiety Disorder (GAD), and is leading the way in developing new treatments for the millions of people living with them. #GAD #Neuropsych #Innovation

GAD (Generalized Anxiety Disorder) involves constant, excessive worry about everyday issues, often without a clear cause, over an extended period of time. Research shows that GAD may stem from various factors, including genetics and increased activity in the brain. External factors such as traumatic events or prolonged periods of stress can also trigger GAD. We aspire to improve the treatment of GAD through research, science, and the novel use of psychedelics.